Several proteins of Porphyromonas gingivalis contain multiple copies of a 47 amino acid conserved repeated sequence. A fusion protein was constructed in which the P. gingivalis peptide was fused to the carboxy terminus of the hepatitis B core protein. This fusion protein was expressed in Escherichia coli, purified, and used to vaccinate mice that were later challenged with P. gingivalis W83 using the mouse abscess model. Although the mice were not protected against bacterial challenge, Western blot analysis showed that sera from the mice and from rabbits immunized with the fusion protein reacted with a number of vesicle proteins from P. gingivalis W83. These data suggested that this peptide is recognized by the host's immune system but that the antibodies are not protective. z
Introduction
Porphyromonas gingivalis has been implicated as a causative agent of periodontal disease, particularly in the etiology of adult-onset periodontitis. Multiple virulence factors have been attributed to this organism, and the most well studied of these are the gingipains, a family of cysteine proteases with speci¢city for arginine-X or lysine-X peptide bonds [1] . Allelic exchange mutants defective in either the arginine or lysine gingipain have reduced virulence in a mouse abscess model [2, 3] . A 47 amino acid conserved repeated sequence (CRS), corresponding to amino acids 865^911 from Rgp-1 (A55426), is found in both cysteine proteases as well as in several other proteins (Fig. 1) .
The prevalence of the CRS in proteins related to virulence led us to investigate the possibility that immunization with this 47 amino acid peptide might be protective against subsequent bacterial challenge in the mouse abscess model [4] . We chose to make a fusion protein with hepatitis B virus core protein. This protein, with additional peptides of various lengths fused to its carboxyl terminus, can be produced in Escherichia coli and self-assembles into the hepatitis B virus (HBV)-like nucleocapsid particle. This particle formation increases the fusion protein's immunogenicity and simpli¢es its puri¢cation [5] . In this study, we have used the CRS, fused to the core protein of HBV, as a vaccine in mice.
Materials and methods

Bacterial strains and plasmids
P. gingivalis W83 was cultivated as previously described [3] . The cloning vector, pHBVMM, and the puri¢ed recombinant hepatitis B virus core antigen (HBVcAg) were gifts from Darrell Peterson (Department of Biochemistry and Molecular Biophysics, Virginia Commonwealth University).
Fusion protein construction
DNA encoding the 47 amino acid CRS was ampli¢ed by PCR from the chromosome of P. gingivalis W83. The primers, shown in the legend of Fig. 2 , added the restriction sites BamHI and HindIII to the 5P and 3P ends of the sequence, respectively. A stop codon, TAA, was inserted downstream of the CRS coding region. Insert and vector were digested with BamHI and HindIII and both were puri¢ed from an agarose gel. The vector was further treated with shrimp alkaline phosphatase before being ligated with the 160 bp amplicon containing the conserved repeated sequence. The plasmid, with our ampli¢ed repeat sequence cloned at the 3P end of the HBVcAg gene, was electroporated into E. coli TB1 cells and clones were selected by their resistance to Fig. 1 . Alignment of conserved repeated amino acid sequences from various proteins of P. gingivalis. Uppercase letter in the consensus sequence indicates 100% conservation in all genes. The P. gingivalis strain designation is provided if a gene has been sequenced from more than one strain, and the number indicates which copy of the CRS within the protein is shown, with numbering proceeding from amino to carboxy end. The putative ¢bronectin-binding motifs introduced in Table 1 are shown here in boxes. Rgp1, RgpA, PrpRI, and PrtR are arginine-speci¢c proteases. Kgp, PrtK, and PrtP are proteases with lysine speci¢city. HagA and HagD are hemagglutinins and Tla is a TonB-linked adhesin. The primary references for the listed sequences can be found through GenBank, using the accession numbers provided. Sequence analyses were performed using the Genetics Computer Group (Madison, WI, USA) and BLAST programs (http:// www.ncbi.nlm.nih.gov/BLAST/). ampicillin. One of the clones, V2484, was chosen to produce the fusion protein (HBV-Pg protein).
Puri¢cation of the fusion protein
Twenty-four liters of strain V2484 were grown in a New Brunswick Fermentation system. The cells were harvested and HBV-Pg protein was puri¢ed to homogeneity using a previously published method [6] . For use in animals, HBV-Pg protein was further puri¢ed using an FPLC Mono Q column, equilibrated with 50 mM NaPO R bu¡er, pH 6.8. Presence of the fusion protein was determined using an ELISA which employed an antibody produced against HBVcAg (provided by D. Peterson) [6] . Protein concentration was determined using the DC Protein Assay kit (Bio Rad).
Polyclonal antibody production in rabbits
0.5 mg of the puri¢ed HBV-Pg protein in PBS was mixed with Freund's Complete Adjuvant and used to immunize two female, white New Zealand rabbits. Rabbits were boosted after 6 weeks with 0.3 mg HBV-Pg protein mixed with Freund's Incomplete Adjuvant. Two weeks following the boost, sera were collected from the rabbits, and the IgG fraction was puri¢ed with A¤-Gel Blue DEAE (Bio Rad) using the manufacturer's protocol.
Immunization of mice and challenge with P. gingivalis W83
Female Balb/c mice (8^10 weeks) were divided into six groups of ¢ve mice each. Groups A and B received no immunization. Groups C and D were immunized with 40 Wg HBV-Pg protein per mouse. HBV-Pg protein, in PBS, was mixed with alum (4 Wg) and injected into each mouse on top of both shoulders. After 2 weeks, the mice were boosted with 30 Wg protein mixed with 2 Wg alum and injected as before. Groups E and F were immunized with 31 Wg of HBVcAg mixed with 4 Wg alum at the ¢rst immunization and 22 Wg mixed with 2 Wg alum at the boost. These amounts corresponded to the amount of HBVcAg that groups C and D received as part of the HBV-Pg protein. One week later, blood was collected from mice in groups B, D, and F, and sera were prepared and stored at 320³C. The mouse abscess model was used to determine if immunization with HBV-Pg protein provided protection against infection with P. gingivalis W83 [4] . The bacteria were grown and prepared as described elsewhere [3] . Groups B, D, and F were challenged 21 days after immunization with subcutaneous injections of 1U10
IH P. gingivalis W83 cells in 0.1 ml of sterile PBS at two sites on the dorsal surface. Groups A, C, and E were challenged 40 days post-immunization.
Evaluation of antibody production in rabbits and mice
Polyclonal antibodies from rabbit and mouse were screened for reactivity against the HBV-Pg protein and vesicle protein preparations from P. gingivalis W83, prepared as previously described [3] . Puri¢ed HBV-Pg protein or vesicle proteins containing 1 mM NK-p-tosyl-L-lysine chloromethyl ketone (TLCK) were separated on 12% polyacrylamide gels at 200 V, and the proteins were transferred to nitrocellulose membranes using procedures described elsewhere [7] . The membranes were blocked in 2% (w/v) non-fat dry milk before being exposed to the primary antibody for 16 h (diluted 1:600 for rabbit and 1:500 for mouse). Following extensive washes in TBS containing 0.05% Tween, the blots were incubated for 1 h with the appropriate alkaline phosphatase-conjugated secondary antibody (diluted 1:2000). After washing, the blots were developed using Western Blue Stabilized Substrate (Promega). All bu¡ers and wash solutions contained 1% (w/v) sodium azide.
Results and discussion
Production of HBV-Pg fusion protein
The HBV-Pg protein was constructed as shown in Fig. 2 , expressed in E. coli TB1, and puri¢ed to homogeneity. Generally, the amount of protein produced was at least 20 mg l 3I . A total of 400 mg of puri¢ed protein was obtained for further studies.
Immunization of mice and challenge with P. gingivalis W83
The mice in groups D and F, immunized with HBV-Pg protein and HBVcAg, respectively, produced antibody directed against these proteins as determined by ELISA. Levels of antibody against HBV-Pg protein were 43-and 42-fold higher in the mice of groups D and F, respectively, than in the non-immunized group B mice. Antibody that reacted with HBVcAg was present in even greater amounts. Groups D and F mice had levels 174-fold and 146-fold higher, respectively, than group B mice (data not shown). However, when the mice were challenged with P. gingivalis W83, no di¡erence was observed between the control group with no immunization and the experimental groups. All challenged mice were dead within 48 h. Increasing the time period between immunization and challenge (40 versus 21 days) did not a¡ect our experimental outcome.
Previous studies have shown that fusion proteins containing various peptides fused to the carboxyl end of HBVcAg elicited immune responses in rabbits which were the same as those elicited with the wildtype, implying that the peptide neither enhances nor hinders the immune response. These same studies have shown that high titers of antibodies speci¢cally directed against the peptide fused to the HBVcAg were obtained [5] . In our experiments, the mice in group D lacked antibody that reacted more strongly to the HBV-Pg protein than to HBVcAg alone (data not shown), and it could be this lack of a strong immune response to the CRS portion of the HBVPg fusion protein that resulted in our immunized mice being as susceptible to P. gingivalis W83 challenge as the non-immunized or the HBVcAg-immunized groups.
Because the CRS occurs within multiple P. gingivalis proteins, we hypothesized that this peptide might be a vaccine candidate. However, we were unable to show any protection when mice were immunized with the CRS fused to the core antigen of HBV. Many of the proteins containing the CRS have more than one copy of the sequence. While multiple copies of the CRS were present as part of the HBV nucleocapsid particle, there were single copies of the CRS in each fusion protein. Perhaps the multiple copies of the CRS within the P. gingivalis proteins contribute to structural features that our fusion protein lacks. For example, there might be conformational epitopes formed by copies of the CRS at precise locations within one protein. The importance of multiple copies of this sequence is alluded to with the DFEEDT and EVEDT/S motifs which are found within the CRS. Both motifs appear in repeated sequences found within ¢bronectin-binding proteins in Staphylococcus aureus, Streptococcus dysgalactiae, and Streptococcus equisimilis [8] (Table 1) . Similar sequences are found in the CRS of P. gingivalis, mostly as TFEEDG [9] and EVKYT, as shown in Fig. 1 . Thus, both the number of copies and the location of multiple copies within a single protein relative to one another might a¡ect the function of antibodies raised against the CRS.
Reactivity of polyclonal antisera raised against the HBV-Pg fusion protein
Polyclonal antibodies were collected from the sera of immunized rabbits and mice. Western blot analysis showed that the IgG puri¢ed from the rabbits reacted with both the HBV-Pg protein and with several vesicle proteins from P. gingivalis W83. A representative experiment using serum from one rabbit is shown in Fig. 3 . In lane 2, the 75.9 kDa protein could be the 76 kDa protein found in the culture supernatant of an rgpA mutant and the wild-type strain which was immunoreactive with anti-Arg-gingipain IgG [10] . The protein shown by the single band at 62.5 kDa could be the 60 kDa protein described as the Lys-gingipain protease while the 48 kDa protein might be the 50 kDa arginine-speci¢c protease, gingipain [11] . Other prospects for the identity of the 48 kDa protein include the 48 kDa lysine-speci¢c protease [12] . Any of these possibilities are plausible because both the arginine-and lysinespeci¢c proteases contain multiple copies of the CRS which was recognized by our antisera. In lane 1, the puri¢ed HBV-Pg protein produced multiple immunoreactive bands. Those proteins which are larger than 26 kDa are probably various multimeric forms due to the HBVcAg portion of the fusion protein while those smaller are presumably degradative products.
Similar results were seen using polyclonal sera obtained from the immunized mice. A representative Western blot is shown from each group of mice. Antisera from groups B and F, unimmunized and immunized with HBVcAg, respectively, did not react with P. gingivalis W83 vesicle proteins (Fig. 4 , lanes [14] . Other experiments have shown that production of cysteine protease activity by P. gingivalis is related to the size and type of lesions produced and to the overall virulence of the organism in the mouse abscess model (reviewed in [15] ). Deslauriers et al. used the mouse chamber model to demonstrate that immunization with a subsequence peptide of the ¢m-brillin molecule could provide protection against bacterial challenge 40 days post-immunization [16] . It is interesting to note that the presence of antibody directed against the CRS was not protective in the mice. We used HBV-Pg protein and ELISA to screen periodontal patient sera (kindly provided by VCU Clinical Research Center for Periodontal Diseases) to determine if antibody against the CRS was present. Of the 45 sera tested, 39 had varying levels of IgG directed against the HBV-Pg protein (data not shown). However, there was no correlation between the level of antibody against HBV-Pg protein and attachment loss (data not shown).
We have shown that polyclonal rabbit and mouse antisera generated against the HBV-Pg protein crossreact with several P. gingivalis W83 vesicle proteins, indicating the presence and cross-reactivity of the CRS in these proteins. The sizes of some of these proteins correspond to virulence-associated proteins which have already been described [10^12]. Others which appear to contain the CRS have not yet been characterized. The prevalence of this CRS had suggested that it may serve as a target for vaccine development as this would a¡ect several key proteins of the organism that have been shown to be involved in virulence [10,17^19] . These data further suggest the importance of the CRS to recognition of P. gingivalis by the host immune system since animals immunized with the HBV-Pg protein elicited antibodies that reacted with multiple P. gingivalis vesicular proteins and periodontal patient sera contained antibodies which reacted with HBV-Pg protein. Other chimeric vaccines, perhaps with multiple copies of the CRS, may prove more successful, or the use of this or other chimeras may prove successful in other animal models.
